Xiaoshi Wang is a Senior Pharmaceutical Scientist at FDA/CDER/OPQ/OPQAIII. Xiaoshi joined FDA in 2017. In her current role, Xiaoshi leads a product quality review team to support CMC review for protein therapeutics BLAs and supplements, INDs and amendments, pre-approval meetings and inspections. Prior to FDA, Xiaoshi worked on protein-based vaccine development at Novavax, Inc. in the Analytical Development Department. Xiaoshi received a Ph.D. Degree in Chemistry from Princeton University.